Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry
| Autor: | Kenji Sakata, Zenon Huczek, Alberto Garay, Wouter J. Kikkert, Xiantao Song, Danielle A. Southern, Maurizio D'Amico, Tetsuma Kawaji, Jing-Yao Fan, Emilio Alfonso, Takuya Nakahayshi, Michal Kowara, Luis C. L. Correia, Sergio Raposeiras-Roubín, Belén Terol, Stephen B. Wilton, Yan Yan, Masakazu Yamagishi, Helge Möllmann, Shaoping Nie, José Ramón González-Juanatey, Hiroki Shiomi, Dario Celentani, Fiorenzo Gaita, Albert Ariza-Solé, Ioanna Xanthopoulou, Oliver Kalpak, Christoph Liebetrau, Sasko Kedev, Jorge F. Saucedo, Xiao Wang, Yalei Chen, Neriman Osman, Iván J. Núñez-Gil, Fabrizio D'Ascenzo, José María García-Acuña, Alberto Grosso, Dimitrios Alexopoulos, Yuji Ikari, Masa-aki Kawashiri, Claudio Moretti, Alessandro Brustio, José P.S. Henriques, Dongfeng Zhang, Toshiharu Fujii, Emad Abu-Assi, Krzysztof J. Filipiak |
|---|---|
| Přispěvatelé: | Cardiology, ACS - Atherosclerosis & ischemic syndromes |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Acute coronary syndrome medicine.medical_treatment Adrenergic beta-Antagonists 030204 cardiovascular system & hematology Revascularization 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Internal medicine medicine Clinical endpoint Humans Pharmacology (medical) Hospital Mortality Registries 030212 general & internal medicine Myocardial infarction cardiovascular diseases Acute Coronary Syndrome Propensity Score Aged Female Retrospective Studies ST Elevation Myocardial Infarction Treatment Outcome Cardiology and Cardiovascular Medicine Ejection fraction Unstable angina business.industry Percutaneous coronary intervention General Medicine medicine.disease Conventional PCI Cardiology business |
| Zdroj: | American journal of cardiovascular drugs, 18(4), 299-309. Adis International Ltd |
| ISSN: | 1175-3277 |
| Popis: | Purpose: The aim was to evaluate prognostic value of beta-blocker (BB) administration in acute coronary syndromes (ACS) patients in the percutaneous coronary intervention (PCI) era. Methods and Results: The BleeMACS project is a multicenter, observational, retrospective registry enrolling patients with ACS worldwide in 15 hospitals. Patients discharged with BB therapy were compared to those discharged without a BB before and after propensity score with matching. The primary endpoint was all-cause mortality at 1 year. Secondary endpoints included in-hospital reinfarction, in-hospital heart failure, 1-year myocardial infarction, 1-year bleeding and 1-year composite of death and recurrent myocardial infarction. After matching, 2935 patients for each group were enrolled. The primary endpoint of 1-year death was significantly lower in the group on BB therapy (4.5 vs 7%, p < 0.05), while only a trend was noted for recurrent acute myocardial infarction (4.5 vs 4.9%, p = 0.54). These results were consistent for patients older than 80 years of age, for ST-elevation myocardial infarction (STEMI) patients, and for those discharged with complete versus incomplete revascularization, but not for non-STEMI/unstable angina patients. Conclusions: BB therapy was related to 1-year lower risk of all-cause mortality, independently from completeness of revascularization, admission diagnosis, age and ejection fraction. Randomized controlled trials for patients treated with PCI for ACS should be performed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink